Formal Opposition to
Patents Amendment Bill

(Government Bill 154–1, Scott Simpson)

From: Ukes Baha | 30 August 2025

Submitted in response to the call for Patents Amendment Bill


Summary of Position

I oppose the Patents Amendment Bill in its current form.

While framed as a technical measure to “align standards” and “modernise transitional provisions,” the bill in fact undermines fairness, creates arbitrary outcomes, and risks chilling innovation.

It retrospectively alters the legal expectations of applicants who filed under the 1953 Act in good faith, embeds confusing hybrid standards, and privileges large corporates who can afford to adjust claims under stricter rules. Small innovators, universities, and community inventors will face higher barriers, more uncertainty, and less protection for their intellectual property.

Far from “modernisation,” this bill risks entrenching legal inconsistency, undermining trust in the patent system, and discouraging research commercialisation in New Zealand.


1. Retrospective Reach and Natural Justice

Reference: New section 258A; amended s254, s258.

Problem:

Risk:


2. Confusing Hybrid Standards

Reference: s254(3)–(6), s258A.

Problem:

Risk:


3. Arbitrary and Unequal Outcomes

Reference: s258 and s258A filing date criteria.

Problem:

Risk:


4. Risks to Innovation and Small Inventors

Problem:

Risk:


5. Procedural Rights and Oversight

Reference: s254(4)–(5), s258A(3).

Problem:

Risk:


6. Questionable Necessity and Proportionality

Problem:

Risk:


7. International and Treaty Implications

Problem:

Risk:


Conclusion and Recommendations

This bill does not simply “harmonise standards.” It retrospectively alters rights, creates legal uncertainty, undermines small innovators, and risks chilling research commercialisation. It is disproportionate to the problem it seeks to solve and erodes trust in New Zealand’s patent system.

Recommendations:

  1. Withdraw the bill in full.
  2. If reform is pursued, grandparent existing 1953 Act applications—do not retroactively impose 2013 Act standards.
  3. Maintain clear separation between Acts—avoid hybridised transitional provisions.
  4. Protect small innovators and universities from disproportionate impacts.
  5. Limit Commissioner discretion—retain balanced opposition and review rights.
  6. Allow transitional cases to phase out naturally rather than rewriting law for a diminishing group.
  7. Ensure full treaty and TRIPS compliance before altering established patent rights.

Respectfully submitted,
Ukes Baha
Public Health Advocate | Counsellor | Policy Analyst
ukesbaha.com